JP6751756B2 - 低密度リポタンパク質コレステロールレベルを低下させるためのcd24の使用 - Google Patents

低密度リポタンパク質コレステロールレベルを低下させるためのcd24の使用 Download PDF

Info

Publication number
JP6751756B2
JP6751756B2 JP2018510322A JP2018510322A JP6751756B2 JP 6751756 B2 JP6751756 B2 JP 6751756B2 JP 2018510322 A JP2018510322 A JP 2018510322A JP 2018510322 A JP2018510322 A JP 2018510322A JP 6751756 B2 JP6751756 B2 JP 6751756B2
Authority
JP
Japan
Prior art keywords
protein
hours
ldl
subject
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018510322A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018515605A (ja
JP2018515605A5 (cg-RX-API-DMAC7.html
Inventor
リウ, ヤン
ヤン リウ,
パン ジャン,
パン ジャン,
Original Assignee
オンコイミューン, インコーポレイテッド
オンコイミューン, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オンコイミューン, インコーポレイテッド, オンコイミューン, インコーポレイテッド filed Critical オンコイミューン, インコーポレイテッド
Publication of JP2018515605A publication Critical patent/JP2018515605A/ja
Publication of JP2018515605A5 publication Critical patent/JP2018515605A5/ja
Application granted granted Critical
Publication of JP6751756B2 publication Critical patent/JP6751756B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
JP2018510322A 2015-05-07 2016-05-06 低密度リポタンパク質コレステロールレベルを低下させるためのcd24の使用 Expired - Fee Related JP6751756B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562158157P 2015-05-07 2015-05-07
US62/158,157 2015-05-07
PCT/US2016/031109 WO2016179456A1 (en) 2015-05-07 2016-05-06 Use of cd24 for lowering low-density lipoprotein cholesterol levels

Publications (3)

Publication Number Publication Date
JP2018515605A JP2018515605A (ja) 2018-06-14
JP2018515605A5 JP2018515605A5 (cg-RX-API-DMAC7.html) 2019-04-11
JP6751756B2 true JP6751756B2 (ja) 2020-09-09

Family

ID=57218627

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018510322A Expired - Fee Related JP6751756B2 (ja) 2015-05-07 2016-05-06 低密度リポタンパク質コレステロールレベルを低下させるためのcd24の使用

Country Status (18)

Country Link
US (2) US10369197B2 (cg-RX-API-DMAC7.html)
EP (1) EP3292144B1 (cg-RX-API-DMAC7.html)
JP (1) JP6751756B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170141216A (cg-RX-API-DMAC7.html)
CN (1) CN107531772B (cg-RX-API-DMAC7.html)
AU (1) AU2016258084B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017022394A2 (cg-RX-API-DMAC7.html)
CA (1) CA2982612A1 (cg-RX-API-DMAC7.html)
EA (1) EA038520B1 (cg-RX-API-DMAC7.html)
ES (1) ES2829235T3 (cg-RX-API-DMAC7.html)
HK (1) HK1249521A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20201651T1 (cg-RX-API-DMAC7.html)
HU (1) HUE051866T2 (cg-RX-API-DMAC7.html)
IL (1) IL255086B (cg-RX-API-DMAC7.html)
MX (1) MX385941B (cg-RX-API-DMAC7.html)
PT (1) PT3292144T (cg-RX-API-DMAC7.html)
WO (1) WO2016179456A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201706846B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1249521A1 (zh) * 2015-05-07 2018-11-02 肿瘤免疫股份有限公司 Cd24用於降低低密度脂蛋白胆固醇水平的用途
SG11201908077XA (en) * 2017-03-07 2019-09-27 Oncoimmune Inc Methods of use of soluble cd24 for treating systemic lupus erythematosus
WO2019113123A1 (en) * 2017-12-04 2019-06-13 Precithera, Inc. TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING
US20210046154A1 (en) * 2018-03-05 2021-02-18 Oncoimmune, Inc Methods of use of soluble cd24 for treating acquired immune deficiency syndrome (hiv/aids)
TW202015753A (zh) * 2018-06-04 2020-05-01 美商昂科免疫公司 以cd24預防及治療移植物抗宿主病及黏膜炎之方法
KR102559149B1 (ko) 2018-10-26 2023-07-24 에프. 호프만-라 로슈 아게 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법
WO2020163529A1 (en) * 2019-02-06 2020-08-13 Oncoimmune, Inc. Targeting cd24-siglec interactions for the treatment and prevention of nonalcoholic steatohepatitis
US20220000974A1 (en) * 2019-02-06 2022-01-06 Oncolmmune, Inc. Targeting CD24-Siglec Interactions for Treating Subjects with Prediabetes or Diabetes
US20230103352A1 (en) * 2020-02-10 2023-04-06 Oncoimmune, Inc. Methods of use of soluble cd24 for treating sars-cov-2 infection
EP4103217A4 (en) * 2020-02-10 2024-03-13 Oncoimmune Inc. METHOD OF USING SOLUBLE CD24 TO TREAT VIRAL PNEUMONIA

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544566B1 (en) * 1999-04-23 2003-04-08 Protein Technologies International, Inc. Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol
WO2001072325A1 (en) * 2000-03-29 2001-10-04 The Ohio State University Research Foundation Methods of blocking tissue destruction by autoreactive t cells
CN1323544A (zh) * 2000-05-13 2001-11-28 蛋白质技术国际公司 降低低密度脂蛋白胆固醇浓度的组合物和方法
JP2011509244A (ja) * 2007-12-21 2011-03-24 ユニバーシティー オブ ロチェスター 脳の原発性神経腫瘍および神経膠腫における脳腫瘍幹細胞マーカーならびに診断および治療標的としてのcd24
US8163281B2 (en) * 2009-03-04 2012-04-24 The Regents Of The University Of Michigan Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis
US8354520B2 (en) * 2009-12-10 2013-01-15 Kaohsiung Medical University Composition and method for treating atherosclerosis, method for determining if a subject has atherosclerosis and method of screening an anti-atherosclerotic drug
US20130231464A1 (en) * 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
ES2826445T3 (es) * 2010-04-28 2021-05-18 Oncolmmune Inc Uso médico de CD24 soluble
US20140357505A1 (en) * 2011-06-10 2014-12-04 The Trustees Of The University Of Pennsylvania System And Method Of Cytomic Vascular Health Profiling
HK1249521A1 (zh) * 2015-05-07 2018-11-02 肿瘤免疫股份有限公司 Cd24用於降低低密度脂蛋白胆固醇水平的用途

Also Published As

Publication number Publication date
ES2829235T3 (es) 2021-05-31
JP2018515605A (ja) 2018-06-14
ZA201706846B (en) 2018-12-19
EP3292144A1 (en) 2018-03-14
CN107531772A (zh) 2018-01-02
EP3292144B1 (en) 2020-08-26
PT3292144T (pt) 2020-11-05
WO2016179456A1 (en) 2016-11-10
AU2016258084B2 (en) 2020-01-30
HRP20201651T1 (hr) 2020-12-25
US10369197B2 (en) 2019-08-06
HK1249521A1 (zh) 2018-11-02
AU2016258084A1 (en) 2017-11-02
CN107531772B (zh) 2021-09-21
EA038520B1 (ru) 2021-09-09
EP3292144A4 (en) 2018-11-14
US11026995B2 (en) 2021-06-08
US20190307841A1 (en) 2019-10-10
MX385941B (es) 2025-03-18
IL255086A0 (en) 2017-12-31
HUE051866T2 (hu) 2021-03-29
BR112017022394A2 (pt) 2018-07-17
KR20170141216A (ko) 2017-12-22
CA2982612A1 (en) 2016-11-10
MX2017014095A (es) 2018-03-16
IL255086B (en) 2021-08-31
EA201792418A1 (ru) 2018-02-28
US20180110828A1 (en) 2018-04-26

Similar Documents

Publication Publication Date Title
US11026995B2 (en) Use of CD24 for lowering low-density lipoprotein cholesterol levels
JP6888221B2 (ja) 関節リウマチの治療のための可溶性cd24の使用方法
US11472864B2 (en) Polynucleotides encoding APOA1-PON1 fusion polypeptides
US20210162006A1 (en) Use of CD24 Proteins for Treating Leptin-Deficient Conditions
EP4025238A1 (en) Therapeutic fusion proteins
KR20200034957A (ko) 신경 보호 및 재수초화를 위한 가용성 cd24의 사용 방법
KR20190126801A (ko) 전신 홍반성 루푸스를 치료하기 위한 가용성 cd24의 사용 방법
WO2018136163A2 (en) Tandem apoa-1 fusion polypeptides
EP3921339A2 (en) Targeting cd24-siglec interactions for treating subjects with prediabetes or diabetes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190304

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20191028

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20191101

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200702

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200804

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200817

R150 Certificate of patent or registration of utility model

Ref document number: 6751756

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees